(1) Organization AVEO Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Companys pipeline of product candidates under development includes its lead candidate tivozanib for use in oncology and other indications; ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody as a potential treatment for squamous cell carcinoma of the head and neck (HNSCC), acute myeloid leukemia (AML) and pancreatic cancer; AV-203, an anti-ErbB3 monoclonal antibody, as a potential oncology treatment; AV-380, a humanized IgG1 inhibitory monoclonal antibody targeting growth differentiation factor 15 (GDF15), a divergent member of the TGF- family, for the potential treatment of cancer cachexia; and AV-353, which targets the Notch 3 pathway. The Company is working to develop and commercialize tivozanib in North America as a treatment for relapsed or refractory metastatic renal cell carcinoma (RCC). The Company has sublicensed tivozanib, marketed under the brand name FOTIVDA  , in Europe and other territories outside of North America. Through the Companys partner, EUSA Pharma (UK) Limited (EUSA), tivozanib is approved in the European Union (EU), as well as the United Kingdom, Norway, Iceland and New Zealand, for the first-line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor (VEGFR) and mTOR pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for RCC. The Company also has clinical collaborations to study tivozanib in combination with immune checkpoint inhibitors in RCC and in hepatocellular carcinoma (HCC). The Company is seeking to commercialize its oncology pipeline of products and product candidates in North America while leveraging partnerships to support development and commercialization of its pipeline in other geographies. As used throughout these consolidated financial statements, the terms AVEO, and the Company refer to the business of AVEO Pharmaceuticals, Inc. and its three wholly-owned subsidiaries, AVEO Pharma Limited, AVEO Pharma (Ireland) Limited and AVEO Securities Corporation. Liquidity and Going Concern The Company has financed its operations to date primarily through private placements and public offerings of its common stock and preferred stock, license fees, milestone payments and research and development funding from strategic partners, and loan proceeds. The Company has devoted substantially all of its resources to its drug development efforts, comprising research and development, manufacturing, conducting clinical trials for its product candidates, protecting its intellectual property and general and administrative functions relating to these operations. The future success of the Company is dependent on its ability to develop its product candidates and ultimately upon its ability to attain profitable operations. As of December 31, 2019, the Company had cash, cash equivalents and marketable securities totaling approximately $47.7 million, working capital of $29.5 million and an accumulated deficit of $585.6 million. The Company is subject to a number of risks, including the need for substantial additional capital to continue its development programs and to fulfill its planned operating goals. In particular, the Companys currently planned operating and capital requirements include the need for substantial working capital to support the development and commercialization activities for its lead product candidate, tivozanib. The Company intends to submit an NDA to the U.S. Food and Drug Administration at the end of the first quarter of 2020 for tivozanib for the treatment of patients with RCC. As of December 31, 2019, the Company had approximately $47.7 million in cash, cash equivalents and marketable securities. Based on its available cash resources, the Company does not have sufficient cash on hand to fund its current operations for more than twelve months from the date of filing this Annual Report on Form 10-K. This condition raises substantial doubt about the Companys ability to continue as a going concern. The Companys plans to address this condition include pursuing one or more of the following options to secure additional funding, none of which can be guaranteed or are entirely within the Companys control:  Earn royalty payments pursuant to the Companys license agreement with EUSA Pharma (UK) Limited (the EUSA Agreement). In August 2017, EUSA obtained marketing approval from the European Medicines Agency (the EMA) for tivozanib (FOTIVDA) for the treatment of RCC.  Earn milestone payments pursuant to the collaboration and license agreements described in Note 4 or restructure / monetize existing potential milestone and/or royalty payments under those collaboration and license agreements.  Raise funding through the possible additional sales of the Companys common stock, including public or private equity financings and / or sales of the Companys common stock under the Leerink Sales Agreement, as discussed in Note 7.  Partner a portion or all rights to the Companys portfolio candidates to secure potential additional non-dilutive funds. Pursuant to the EUSA Agreement, the Company is entitled to receive up to an additional $4.0 million in milestone payments of $2.0 million per country upon reimbursement approval for RCC, if any, in each of France and Italy, and an additional $2.0 million milestone payment for the grant of marketing approval, if any, in three of the licensed countries outside of the EU, as mutually agreed by the parties. These milestone payments are subject to the 30% sublicense fee payable to Kyowa Kirin Co. (formerly Kirin Brewery Co., Ltd.) (KKC) pursuant to the Companys license agreement with KKC (the KKC Agreement). The Company is also eligible to receive an additional research and development reimbursement payment from EUSA of 50% of the total costs for the Companys TIVO-3 trial, up to $20.0 million, if EUSA elects to opt-in to that study. This research and development reimbursement payment would not be subject to the 30% sublicense fee payable to KKC, subject to certain limitations. Refer to Note 4  Collaborations and License Agreements - KKC  f or further details. There can be no assurance, however, that the Company will receive cash proceeds from any of these potential resources or to the extent cash proceeds are received such proceeds would be sufficient to support the Companys current operating plan for more than twelve months from the date of filing this Annual Report on Form 10-K. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entitys Ability to Continue as a Going Concern (ASC 205-40) management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Companys ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of managements plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Companys ability to continue as a going concern. The mitigating effect of managements plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entitys ability to continue as a going concern within one year after the date that the financial statements are issued. Under ASC 205-40, the future receipt of potential funding from the Companys collaborators and other resources cannot be considered probable at this time because none of the Companys current plans have been finalized at the time of filing this Annual Report on Form 10-K and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Companys control. Accordingly, substantial doubt is deemed to exist about the Companys ability to continue as a going concern within one year after the date these financial statements are issued. If the Company is unable to obtain sufficient capital to continue to advance its programs, the Company would be forced to delay, reduce or eliminate its research and development programs and any future commercialization efforts. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.